Polyrizon Files Divisional Patent Application for Trap & Target Technology in Israel
Raanana, Israel, January 30, 2025 – Polyrizon Ltd. (PLRZ), a pioneering biotech company specializing in the development of innovative intranasal hydrogels, has announced the filing of a divisional patent application with the Israel Patent Office. This application focuses on protecting the Company’s advanced intranasal drug delivery system, Trap & Target (T&T) platform technology.
Advanced Intranasal Drug Delivery System: Trap & Target
The T&T platform technology is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. This technology aligns with Polyrizon’s recently announced U.S. patent application, which encompasses key aspects of the Company’s two core platform technologies: Capture and Contain (C&C) and Trap and Target (T&T).
Understanding Polyrizon’s Core Platform Technologies
The C&C technology is a nasal blocker designed to prevent the backflow of medications, ensuring they remain in the nasal cavity for an extended period. The T&T technology, on the other hand, is an advanced drug delivery system that utilizes specific molecular structures to trap and target drugs directly to the affected area in the nasal cavity.
Impact on Individuals
For individuals suffering from chronic nasal conditions, such as allergies or sinusitis, these advancements in intranasal drug delivery systems could lead to more effective treatments. The ability to keep medications in contact with the affected tissues for longer periods and deliver them directly to the target area could result in improved symptoms and better overall health.
- More effective treatments for chronic nasal conditions
- Improved symptoms and better overall health
- Potential for fewer side effects due to targeted drug delivery
Impact on the World
Beyond individual benefits, these advancements in intranasal drug delivery systems could have a significant impact on the global healthcare industry. With an aging population and a growing prevalence of chronic conditions, the demand for effective, non-invasive treatments is increasing. T&T technology could lead to:
- Reduced healthcare costs by providing more effective treatments for chronic conditions
- Improved patient quality of life by addressing the root cause of chronic nasal conditions
- A potential shift towards non-invasive treatments, reducing the need for surgeries and invasive procedures
Conclusion
Polyrizon’s filing of a divisional patent application for its Trap & Target technology in Israel marks a significant step forward in the development of innovative intranasal drug delivery systems. This technology, combined with the Capture and Contain technology, has the potential to revolutionize the treatment of chronic nasal conditions, improving individual health and reducing healthcare costs on a global scale. As research and development continue, we can look forward to a future where effective, non-invasive treatments are the norm.
Polyrizon’s commitment to innovation and its focus on addressing unmet medical needs make it an exciting company to watch in the biotech industry. Stay tuned for further updates on their progress and the potential impact on healthcare and individual lives.
